Chemomab Therapeutics awarded European patent for CM-101

Chemomab Therapeutics reported that the European Patent Office has granted a new patent for CM-101, Chemomab’s first-in-class monoclonal antibody that neutralizes CCL24, a novel disease target that has been shown to play a critical role in the processes that drive fibrosis and inflammation. CM-101 is currently being assessed in the global Phase 2 SPRING trial for the treatment of primary sclerosing cholangitis. Patient enrollment in the trial has been completed, with a topline data readout expected midyear 2024. The new European patent covers the use of CM-101 and sequence-related anti-CCL24 antibodies for the treatment of hepatic diseases, including PSC. PSC is a potentially lethal condition that lacks any FDA-approved therapies and frequently requires liver transplantation. Unlike other drugs in development for PSC, CM-101 has a unique dual mechanism of action that simultaneously blocks fibrosis and inflammation. In clinical and preclinical studies, this distinctive approach has been shown to inhibit fibrogenesis and interfere with core PSC pathways. European Patent Application No. 18717135.0 “Anti CCL24 Antibodies for Use in the Treatment of Hepatic Diseases” has a grant date of March 20, 2024.